Eledon Pharmaceuticals Inc
NASDAQ:ELDN
Eledon Pharmaceuticals Inc
NASDAQ:ELDN
Price:
2.21
USD
0.91%
Market Closed
Market Cap:
$165.8m
Balance Sheet
Balance Sheet Decomposition
Eledon Pharmaceuticals Inc
Eledon Pharmaceuticals Inc
Balance Sheet Decomposition is not available for
Eledon Pharmaceuticals Inc
Eledon Pharmaceuticals Inc
Balance Sheet
Eledon Pharmaceuticals Inc
Eledon Pharmaceuticals Inc
Currency: USD
| Dec-2012 | Dec-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||
| Cash & Cash Equivalents |
12
|
32
|
105
|
24
|
23
|
17
|
13
|
9
|
114
|
85
|
56
|
5
|
21
|
|
| Cash Equivalents |
12
|
32
|
105
|
24
|
23
|
17
|
13
|
9
|
114
|
85
|
56
|
5
|
21
|
|
| Short-Term Investments |
0
|
0
|
0
|
40
|
4
|
0
|
0
|
0
|
0
|
0
|
0
|
46
|
120
|
|
| Total Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Assets |
0
|
0
|
2
|
3
|
2
|
2
|
1
|
1
|
1
|
4
|
3
|
5
|
4
|
|
| Total Current Assets |
12
|
32
|
108
|
67
|
30
|
19
|
14
|
10
|
116
|
88
|
60
|
56
|
144
|
|
| PP&E Net |
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
0
|
1
|
|
| PP&E Gross |
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Intangible Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
32
|
32
|
32
|
32
|
32
|
|
| Goodwill |
0
|
0
|
0
|
0
|
0
|
2
|
2
|
0
|
49
|
49
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
|
| Other Assets |
0
|
0
|
0
|
0
|
0
|
2
|
2
|
0
|
49
|
49
|
0
|
0
|
0
|
|
| Total Assets |
12
N/A
|
32
+169%
|
108
+233%
|
68
-37%
|
30
-56%
|
21
-30%
|
17
-19%
|
11
-36%
|
197
+1 709%
|
171
-14%
|
93
-46%
|
89
-4%
|
177
+99%
|
|
| Liabilities | ||||||||||||||
| Accounts Payable |
1
|
0
|
1
|
1
|
0
|
0
|
1
|
0
|
1
|
2
|
2
|
1
|
6
|
|
| Accrued Liabilities |
1
|
2
|
4
|
5
|
2
|
1
|
2
|
1
|
1
|
3
|
4
|
3
|
6
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Current Liabilities |
2
|
2
|
4
|
6
|
3
|
1
|
3
|
1
|
3
|
4
|
7
|
4
|
12
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Deferred Income Tax |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
4
|
2
|
2
|
2
|
2
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
46
|
|
| Total Liabilities |
2
N/A
|
2
+10%
|
4
+91%
|
6
+50%
|
3
-54%
|
1
-52%
|
3
+79%
|
2
-40%
|
7
+340%
|
7
N/A
|
9
+30%
|
6
-34%
|
59
+949%
|
|
| Equity | ||||||||||||||
| Common Stock |
50
|
85
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
47
|
63
|
86
|
131
|
169
|
28
|
42
|
58
|
80
|
115
|
203
|
243
|
356
|
|
| Additional Paid In Capital |
7
|
8
|
190
|
193
|
196
|
47
|
56
|
67
|
271
|
279
|
287
|
327
|
474
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
10
N/A
|
30
+204%
|
104
+244%
|
62
-40%
|
27
-56%
|
20
-28%
|
15
-26%
|
10
-34%
|
191
+1 906%
|
164
-14%
|
84
-49%
|
83
-1%
|
118
+42%
|
|
| Total Liabilities & Equity |
12
N/A
|
32
+169%
|
108
+233%
|
68
-37%
|
30
-56%
|
21
-30%
|
17
-19%
|
11
-36%
|
197
+1 709%
|
171
-14%
|
93
-46%
|
89
-4%
|
177
+99%
|
|
| Shares Outstanding | ||||||||||||||
| Common Shares Outstanding |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
15
|
14
|
14
|
24
|
60
|
|
| Preferred Shares Outstanding |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Switch to:
Switch to:
See Also
Discover More
